Clik here to view.
組換えコロナウイルス（SARS-CoV-2）ワクチン「ヌバキソビッド®筋注」の日本における初回免疫、および追加免疫を含む製造販売承認取得について
大阪、日本＆ケンブリッジ、マサチューセッツ。 （ビジネスワイヤ） — 当社は、本日、組換えスパイクタンパクを抗原とした新型コロナウイルス感染症ワクチン 「ヌバキソビッド®筋注」（開発コード：TAK-019、以下「ヌバキソビッド」）について、18歳以上を対象として、厚生労働省より初回免疫および追加免疫に対する製造販売承認を取得しましたのでお知らせます。当社は、Novavax,...
View ArticleClik here to view.
ENHERTU® Granted Priority Review in the U.S. for Patients with Previously...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have received notification of acceptance of the supplemental Biologics License Application (sBLA) of...
View ArticleClik here to view.
Turnstone Biologics Announces Executive Leadership Appointments
NEW YORK Turnstone Biologics Corp., a clinical-stage biotechnology company developing next-generation tumor-infiltrating lymphocyte (“TIL”) therapy and viral immunotherapy designed to treat and cure...
View ArticleClik here to view.
BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and...
View ArticleClik here to view.
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent...
DUBLIN, Ohio Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics,...
View ArticleClik here to view.
Clik here to view.
Clik here to view.
Vaxxas Announces Appointment of Scott Fry Ph.D. as Chief Operating Officer
CAMBRIDGE, Mass. & BRISBANE, Australia Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, is pleased to announce a key appointment to its executive...
View ArticleClik here to view.
Turnstone Biologics Announces TIL Therapy Research Collaboration with the...
NEW YORK Turnstone Biologics Corp., a clinical-stage biotechnology company developing next-generation tumor-infiltrating lymphocyte (“TIL”) therapy and viral immunotherapy designed to treat and cure...
View ArticleClik here to view.
Porton Advanced and Sinorda Biomedicine Enter Strategic Collaboration to...
SUZHOU, China Suzhou Porton Advanced Solutions Ltd. (‘Porton Advanced’) and Guizhou Sinorda Biomedicine Co. Ltd (‘Sinorda Biomedicine’) today announced a long-term strategic partnership in cell and...
View ArticleClik here to view.
Dalrada Health’s cerVIA™ Test Kit Enables Immediate Results with Second...
SAN DIEGO Dalrada Corporation (OTCQB: DFCO, “Dalrada”), an innovator in healthcare, green energy, and technology, today announced that the Company completed a second clinical trial on its...
View ArticleClik here to view.
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in the Supply...
View ArticleClik here to view.
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD)...
View ArticleClik here to view.
Global Phase 3 Trial of BeiGene’s PD-1 Inhibitor, Tislelizumab, in...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and...
View ArticleClik here to view.
Trial Master File Reference Model Group Officially Affiliates with CDISC
AUSTIN, Texas CDISC today announced an expansion of its offerings with the official affiliation of volunteer-based Trial Master File (TMF) Reference Model Group. The combined organizations will...
View ArticleClik here to view.
Asian Fund for Cancer Research Announces Chimera Bioengineering as the 2021...
HONG KONG Chimera Bioengineering has been selected as the winner of the Asian Fund for Cancer Research’s (AFCR) 2021 BRACE Award Venture Competition—a first-of-its-kind program for early stage...
View ArticleClik here to view.
武田荣获2022年国际制药工程协会年度设施奖两项大奖
日本大阪和马萨诸塞州剑桥市 (美国商业资讯)—武田(Takeda, TSE:4502/NYSE:TAK)今天宣布，国际制药工程协会(ISPE)在2022年度设施奖 (FOYA)的供应链和Pharma 4.0™类别中授予公司最高荣誉。在供应链类别中，武田凭借为异体间充质干细胞疗法实施以患者为中心的新供应链而获奖；武田位于德国辛根的疫苗生产设施则在Pharma 4.0类别中获奖。...
View ArticleClik here to view.
Clik here to view.
Genome Insight Draws $23 Million in Series B Funding to Open the Whole Genome...
SAN DIEGO Genome Insight, a global leader in Whole Genome Sequence analysis and interpretation, announced $23 million in Series B funding. Dunamu & Partners led the financing with participation...
View ArticleClik here to view.
知临集团提供有关其针对神经母细胞瘤的项目SACT-1的已完成1 期临床试验数据更新
纽约、伦敦和巴黎 临床阶段生物制药公司知临集团有限公司（纳斯达克代码：APM，巴黎泛欧证券交易所代码：APM）（「知临集团」或「知临」）欣然宣布 SACT-1 的 1期临床试验的最终数据。SACT-1是一种针对神经母细胞瘤和潜在其他癌症类型的重新利用的小分子药物。 继 2022 年 1 月宣布 SACT-1 的 1...
View Article